The Role of PDGFs and PDGFRs in Colorectal Cancer

Table 2

Agents approved as anti-PDGF/PDGFR.

Drug	Target	Type of cancer
Sorafenib (Nexavar)	VEGFR, PDGFRs, FGFR1, KIT, RAF	Metastatic RCC
		Unresectable HCC
Sunitinib (Sutent)	VEGFRs, PDGFRs, KIT, FLT-3	Metastatic RCC
		GIST
		Unresectable pancreatic neuroendocrine tumors
Pazopanib (Votrient)	VEGFRs, PDGFRs, KIT	Metastatic RCC
		Advanced soft tissue sarcoma
Axitinib (Inlyta)	VEGFRs, PDGFRs, KIT	Metastatic RCC
Regorafenib (Stivarga)	VEGFRs, TIE2, PDGFRs, RET, KIT, FGFRs	Metastatic CRC
		GIST

RCC, renal cell carcinoma; VEGFR, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; KIT, v-kit feline sarcoma viral oncogene homolog; RAF, v-raf-1 murine leukemia viral oncogene homolog 1; HCC, hepatocellular carcinoma; FLT-3, fms-related tyrosine kinase 3; GIST, gastrointestinal stromal tumor; RET, ret protooncogene; TIE, tyrosine kinase endothelial.